Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00042560-200206010-00018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.
Nat Commun
January 2025
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate's contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.
View Article and Find Full Text PDFClinical events associated with poor CD4 T-cell recovery in people living with HIV following ART: a systematic review and meta-analysis.
J Infect
January 2025
Research Center for Clinical Medicine, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China; Department of Science and Research, The Affiliated Anning First People's Hospital of Kunming University of Science and Technology, Kunming 650300, China; Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, Kunming Medical University, Kunming 650500, China; School of Basic Medical Sciences, Kunming University of Science and Technology, Kunming 650500, China. Electronic address:
Background: Antiretroviral therapy (ART) has significantly improved outcomes for people living with HIV (PLWH), but poor CD4 T-cell recovery remains a challenge. This study aimed to evaluate the relationship between poor CD4 T-cell recovery and the morbidity of clinical events (CEs) in PLWH after ART initiation.
Methods: We conducted a comprehensive search of the EMBASE, PubMed, Web of Science, and Cochrane Library databases up to February 19, 2024, and included studies that reported the number of CEs along with the CD4 count at the time of the CEs or the most recent CD4 count prior to the CEs.
Plasma galectin-9 levels correlate with blood monocyte turnover and predict simian/human immunodeficiency virus disease progression.
Transl Med Commun
January 2024
Department of Anatomy, Physiology, & Cell Biology, School of Veterinary Medicine, and California National Primate Research Center, University of California, Davis, County Road 98 & Hutchison Drive, Davis, CA, USA.
Background: Late-stage human immunodeficiency virus (HIV) infection is typically characterized by low CD4 + T-cell count. We previously showed that profound changes in the monocyte turnover (MTO) rate in rhesus macaques infected by the simian immunodeficiency virus (SIV) outperforms declining CD4 + T-cell counts in predicting rapid health decline associated with progression to terminal disease. High MTO is associated with increased tissue macrophage death.
View Article and Find Full Text PDFA qualitative study to understand the facilitators of and barriers to retention in care to the national PMTCT Option B+ programme in Uganda.
PLoS One
January 2025
Monitoring and Evaluation Technical Support, Makerere University School of Public Health, Kampala, Uganda.
Introduction: Effective prevention of mother to child transmission (PMTCT) programmes require women and their infants to have access to a cascade of HIV care and treatment interventions. Retention in care reduces the risk of vertical transmission and opportunistic infections among mothers living with HIV. Uganda has made great strides in ensuring the success of the prevention of mother to child transmission program.
View Article and Find Full Text PDFEffect of antiretroviral therapy on the mortality of HIV-1 infection long-term non-progressors: a cohort study.
BMC Infect Dis
January 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning, Guangxi, 530021, China.
Background: The study aims to investigate the demographic characteristics, the variations in their immune status, and mortality risk among HIV-1 infection long-term non-progressors (LTNP).
Methods: Eligible LTNP and typical progressors (TP) were recruited in Guangxi by December 2018. Participants were followed up until December 2022, monitoring ART status, CD4 T cell counts, and survival/death outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!